Bisphosphonates in breast cancer: Teaching an old dog new tricks

Current Opinion in Oncology

Volumn 21, Issue 6, 2009, Pages 499-506

  Winter, Matthew C ^a   Coleman, Robert E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Antitumour; Bisphosphonate; Bone metastases; Bone mineral density; Breast cancer

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PACLITAXEL; PAMIDRONIC ACID; PHARMACOLOGICAL BIOMARKER; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BONE ATROPHY; BONE DENSITY; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; HIGH RISK PATIENT; HUMAN; JAW OSTEONECROSIS; LOW DRUG DOSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; SOFT TISSUE CANCER; TREATMENT OUTCOME; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; OSTEOLYSIS; OSTEOPOROSIS;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 73849142181     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328331c794     Document Type: Review

References (50)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593.
2. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4:30-34.
3. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88 (12 Suppl):2961-2978. (Pubitemid 30413179)
4. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-589.
5. Pavlakis N, Schmidt R, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005: CD003474.
6. Kohno N, Aogl K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23:3314-3321. (Pubitemid 46243475)
7. Rosen LS, Gordon D, Tohekmedylan NS, et al. Long-term efficacy and safety of zoledronlc acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613-2621. (Pubitemid 38715767)
8. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59-69.
9. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89:2031-2037.
10. Coleman RE, Major P, Upton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronlc acid. J Clin Oncol 2005; 23:4925-4935. (Pubitemid 46223998)
11. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronlc acid. Cancer 2008; 113:193-201. (Pubitemid 351976401)
12. Lipton A, Cook RJ, Major P, et al. Zoledronlc acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007; 12:1035-1043. (Pubitemid 350007015)
13. demons M, Dranitsaris G, Ooi W, Cole DE. A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 2008; 108:79-85.
14. demons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006; 24:4895-4900.
15. Body JJ, Lichinitser M, Tjulandin S, et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Onool 2007; 18:1165-1171. (Pubitemid 47244361)
16. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABdSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9:840-849.
17. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Onool 2007; 25:820-828. (Pubitemid 350002882)
18. Hines SL, Mincey BA, Sloan JA, et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009; 27:1047-1053.
19. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Onool 2008; 26:1051-1057.
20. Brufsky A, Harker WG, Beck JT, et al. Zoledronlc acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25:829-836. (Pubitemid 350002883)
21. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronlc acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008; 112:1001-1010. (Pubitemid 351304583)
22. Eidtmann H, Bundred NJ, DeBoer R, et al. The effect of zoledronlc acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZOFAST. Cancer Res 2009; 69(Suppl2):44.
23. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast dancer 2009; 9:77-85.
24. Van Poznak CH, Hannon RA, dlack G, et al. Managing cancer treatmentinduced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE), Cancer Res 2009; 69(Suppl2): 1137.
25. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-lnduced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin dancer Res 2008; 14:6336-6342.
26. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann dncol 2008; 19:1407-1416.
27. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (Suppl 1):S3-S18.
28. Neville-Webbe HL, Rostaml-Hodjegan A, Evans CA, et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosls by doxorubicin in breast and prostate cancer cells. Int J dancer 2005; 113:364-371.
29. dttewell PD, Monkkonen H, Jones M, et al. Antitumor effects of doxorubicin followed by zoledronlc acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100:1167-1178.
30. Winter MC, Thorpe HC, Burkinshaw R, et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct antitumour activity in breast cancer. Cancer Res 2009; 69(Suppl2):5101.
31. Winter MC, Cross SS, Ingram CE, et al. ANZAC: a neoadjuvant blomarker study exploring the antitumour activity of the addition of zoledronlc acid to chemotherapy in breast cancer, [abstract #165P] Annals of Oncology 2009; 20 (Suppl 2).
32. Winter MC, Holen I, Coleman RE. Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34: 453-475.
33. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13 (15 Pt 1):4482-4486. (Pubitemid 47219717)
34. Daubine F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer inst 2007; 99:322-330. (Pubitemid 47073494)
35. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Onool 2008; 19:2007-2011.
36. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363. (Pubitemid 28363797)
37. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast dancer Res 2006; 8:R13.
38. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin dncol 2002; 20:3219-3224. (Pubitemid 34831518)
39. Saarto T, Blomqvist d, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin dncol 2001; 19:10-17. (Pubitemid 32063474)
40. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta dncol 2004; 43:650-656. (Pubitemid 39563937)
41. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral Pamidronate versus no Pamidronate in patients with primary breast cancer. Acta dnool 2008; 47:740-746. (Pubitemid 351878444)
42. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-691.
43. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J dancer 2007; 96:1796-1801. (Pubitemid 46912011)
44. Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow [abstract 510]. In: Proceedings of the 30th Annual San Antonio Breast dancer Symposium; 2007.
45. Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer [Abstract 511]. In: Proceedings of the 30th Annual San Antonio Breast dancer Symposium; 2007.
46. Solomayer E, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTd) in primary breast cancer patients, Cancer Res 2009; 69(Suppl2):2048.
47. doleman RE, Thorpe H, Cameron D, et al. Zoledronlc acid is well tolerated and can be safely administered with adjuvant chemotherapy - first safety data from the AZURE trial (BIG01 /04) [abstract 2080]. In: Proceedings of the 29th Annual San Antonio Breast Cancer Symposium, 14-17 December 2006.
48. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a taskforoe of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-1491.
49. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23:826-836. (Pubitemid 351768801)
50. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer institute of Milan. Ann Oncol 2009; 20:137-145.